sulphonylureas are the drug of choice when treating patients with
HNF1A-diabetes (also known as MODY3). However, no study have investigated
combination treatment. This study will provide insight into if combination of
incretin based treatment and sulphonylurea may be a good treatment option in
patients with HNF1A-diabetes. This study is a glucose-clamp study, where
patients will receive combinations of GLP-1, GIP and glimepiride. The effects
on insulin and glucagon will be investigated.